Actinobacteria and Myxobacteria – Two of the most important bacterial resources for novel antibiotics

Wiebke Landwehr, Corinna Wolf, Joachim Wink*

Helmholtz Centre for Infection Research, Microbial Strain Collection, Inhoffenstrasse 7, 38124 Braunschweig, Germany

*Corresponding author, Joachim.wink@helmholtz-hzi.de

Introduction

Bacteria, have been by far the most promising resource for antibiotics in the past decades and will in all undoubtedly remain an important resource of innovative bioactive natural products in the future. Actinobacteria have been screened for many years, whereas the Myxobacteria have been underestimated in the past. Even though Actinobacteria belong to the Gram positive and Myxobacteria to the Gram negative bacteria both groups have a number of similar characters, as they both have huge genomes with in some cases more than 10kB and a high GC content and they both can differentiate and have often cell cycles including the formation of spores. Actinobacteria have been used of the antibiotic research for many years, hence it is often discussed whether this resource has now been exhaustively exploited but most of the screening programs from pharmaceutical companies were basing on the cultivation mainly of members of the genus *Streptomyces* or *Streptomyces* like strains (e.g. some *Saccharopolyspora*, *Amycolatopsis* or *Actinomadura* species) by use of standard methods the so many of the so called “neglected” Actinobacteria were overlooked the whole time. The present review gives an overview on the state of the art regarding new bioactive compounds with a focus on the marine habitats. Furthermore, the evaluation of Myxobacteria in our ongoing search for novel anti-infectives is highlighted.

1. Marine Actinobacteria	1
1.1. Introduction	1
1.2. Marine Actinobacteria?	1
1.3. Where can you find marine Actinobacteria	4
1.4. Isolation of marine Actinobacteria	5
1.5. Bioactive substances from marine Actinobacteria	7
2. Myxobacteria – the underestimated bacterial resource	10
2.1. History of myxobacteria	10
2.2. Isolation methods	14
2.3. Genetical potential	16
2.4. Pharmaceutically important secondary metabolites	17

1. Marine Actinobacteria

1.1. Introduction

Over the last years, the commercial natural product research came back into focus because “the pipeline for new antibiotics is running dangerously low” (Fenical & Jensen 2006). While the rate of newly discovered antibiotics from soil inhabiting Actinobacteria decreased the rate of re-isolation increased (Fenical et al. 1999; Lam 2006). However, to further explore this promising source of novel bioactive secondary metabolites, new strains had to be isolated with alternative methods or in unexplored environments (Lam 2006). Therefore, not only isolation techniques, but also the sampling sites had to be altered. With 70% of the earth surface and a microbial abundance of 10^6 per mL in sea water and 10^9 per mL in ocean bottom, oceans are the world’s biggest environment (Fenical and Jensen 2006). However, not only sea water and sediments are microbial rich environments, also marine organisms, flora and fauna like sponges harbour abundant communities (Ward & Bora 2006).

1.2. Marine Actinobacteria?

Over a long time, it was not clear whether truly “marine” Actinobacteria really exist because of the fact that there has been a lot of re-isolation of terrestrial strains and known compounds (Moore 2005). The explanation for this assumption was the wash-in from terrestrial spores into the sea (Goodfellow & Haynes 1984) and the sampling problems of marine samples which were taken mostly close to the coast (Fenical & Jensen 2006). However, in the year 1984 the first marine Actinobacterium was found: *Rhodococcus marinonscens* (Helmke & Weyland 1984). 7 Years later, in 1991, the first marine Actinobacteria genus “*Salinispora* spp.” which obligately requires seawater for growth (Jensen et al. 1991) was published. But even with the application of DNA sequence-based methods and the corresponding ability to analyse the relationships between this genus and their terrestrial relatives the first seawater-obligate Actinobacteria genus “*Salinospora*” (grammatically incorrect; corrected to *Salinispora*) was described in 2005 (Mincer et al. 2005) and its two species *Salinispora tropica* and *Salinispora arenicola* were published (Maldonado et al. 2005a). Moreover, with the help of the type strains of these species, which are actively growing in sediment samples, the metabolic activity in the natural marine environment was demonstrated (Mincer et al. 2005). In addition to this finding, Fenical and Jensen (2006) also detected uncommon secondary metabolites produced by *Salinispora* strains and were inspired to further search for new groups of marine Actinobacteria. With the help of 16S analysis of the phylogenetic diversity as well as new cultivation approaches, Starch and Bull (2005) demonstrated that deep sea sediments contained more than 1300 different actinobacterial operational taxonomical units which led to the assumption that there is a great opportunity to find novel species and genera. Fenical and Jensen (2006) cultivated diverse strains within six Actinobacteria families and many of them seemed to represent new taxa like *Salinispora* and *Mariniphilus* (Fig. 1). In addition to the taxonomic findings and therefore the demonstration of the existence of marine Actinobacteria, these strains turned out to be “excellent producers for secondary metabolites”.

Figure 1: Tree illustrating the phylogenetic relationships of 13 groups of marine-derived Actinobacteria within six different families. The taxonomic status of the MAR groups is not really clear whereas it is known that they include numerous of new species. However, the MAR1 group was described as the genus *Salinispora* and the MAR2 group as the genus *Marinispora* (modified after Fenical and Jensen 2006).

1.3. Where can one find marine Actinobacteria?

The geographical origin of the new actinobacterial producer strains, published compounds and bioactivities of 67% of marine natural products (up to 2003) was restricted to Japan, the Mediterranean as well as the Western Pacific Ocean (Blunt et al. 2007; Bull & Starch, 2007). However, because of the growing focus on the research on marine natural products, a dramatic rise of the published data from the China Sea was observed just one year later (Bull & Starch 2007). Marine Actinobacteria are present in diverse marine habitats, which are widespread over the ocean. These habitats are influenced by numerous geographical as well as physical parameters like temperature and salinity. Furthermore, they underlie geochemical impacts and ocean currents. But also ecosystems like salt marshes, wetlands, estuaries, continental shelves as well as the open ocean and the deep sea are habitats for specialised marine Actinobacteria (Ward & Bora 2006). The marine habitat starts with the sea surface microlayer, followed by the water column, from a few millimetres below the surface to more than 10 000 meters depth, down to the sea floor with the micro- and macro-fauna and –flora, which were used as host for epibiosis and symbiosis, as well as the sea subfloor and deep biosphere. Within the habitat of the sea floor, varying sediments of varying geology, mineral nodule fields, carbonate mounds, cold seeps, hydrocarbon seeps, saturated brines and hydrothermal vents were observed (Ward & Bora 2006).

The sea surface microlayer is an environment which is to date poorly characterized. However, some studies showed the existence of Actinobacteria and Proteobacteria within this habitat (Ward & Bora 2006). In the water column, together with the β -Proteobacteria and δ -Proteobacteria, Firmicutes, Cytophaga-Flavobacter-Bacteriodes (CFGs) and Chlorobia, Actinobacteria belong to the mid-range of abundance. α - and γ -Proteobacteria dominated this habitat. Interestingly, these compositions of strain collectives were found in coastal and pelagic waters, despite differences in isolation techniques used and scale (Ward & Bora 2006).

Marine sediments are the best known source for the isolation of Actinobacteria from marine habitats. Studies on the 16S rRNA to detect the phylogenetic diversity of Actinobacteria in marine sediments showed that some deep-sea sediment contained up to 13 000 different actinobacterial operational taxonomic units which are forecast to belong to a large number of novel species and genera (Starch & Bull 2005). Also cultivation approaches of a range of depths and sediments (Maldonado et al. 2005b; Kim et al. 2004; Takami et al. 1997) illustrate the diversity and new insights in Actinobacteria classification (Maldonado et al. 2005a) and biogeography. These insights were used as inspirations for the isolation and recognition of novel marine Actinobacteria (Magarvey et al. 2004; Ward & Bora 2006). Furthermore, molecular studies on three different structural types of stromatolites (“organisms that have been present in the fossil record from greater than 3.5 billion years ago”, cf. Ward & Bora 2006) ensured the presence 6-9% of actinobacterial clones in the their complex mat community (Papineau et al. 2005).

However, there are not only the upper centimetres of marine sediments harbouring Actinobacteria but also the below sea subfloor and the deep biosphere were found to be a natural habitat for these bacteria. Up to a depth of 800 meters, a minor fraction of Actinobacteria were isolated (Starch et al. 2003; Inagaki et al. 2003) and molecular studies with specific primers showed a high actinobacterial diversity in clone libraries (Starch et al. 2003).

Moreover, marine Actinobacteria even live in marine organisms like many free swimming as well as sessile vertebrates and invertebrates. These organisms are mostly known to produce bioactive metabolites but these substances are often produced by symbiotic living microorganisms. The pufferfish for example, was for a long time supposed to be the producer of the potent neurotoxin tetrodotoxin (TTX). However, to date this substance is known to be produced by numerous of marine organisms. Additionally, the production could also be correlated to many taxa of marine bacteria which live in symbiotic relationships with these organisms. In case of the pufferfish, a TTX producing Actinobacteria (closely related to *Nocardiopsis dassonvillei*) and some TTX producing *Bacillus* strains were isolated out of its ovaries which are known to harbour high levels of TTX (Wu et al. 2005; Ward & Bora 2006). With the help of a sodium channel blocker assay using a mouse neuroblastoma cell culture bioassay, toxicity levels of 0.1-1.6 MU/g bacteria cells were observed (MU: amount of toxin which was expressed, calculated from the observed cell ratio (relationship between survival cell ratio and authentic TTX amount)) (Wu et al. 2005; Ward & Bora 2006). Furthermore, some TTX producing Actinobacteria like *Micrococcus* spp. and *Streptomyces* spp. were isolated out of deep sea and marine sediment (Do et al. 1990; Do et al. 1991) which support the assumption that the symbiotic living organisms are responsible for the TTX production. However, to date the biosynthesis of TTX in bacteria or other organisms has not been described (Chau et al. 2011).

Furthermore, marine invertebrates such as sponges were described as natural habitat for marine Actinobacteria. They are known over a long time to be a prolific source of bioactive substances. Because of the reason that they are sessile organisms, they use the bioactive metabolites as a kind of chemical defence (Hill 2004; Ward & Bora 2006). However, up to 35% of sponge biomass is comprised of microorganisms, which build an abundant microbial community (Hetschel et al. 2012; Webster and Taylor 2012; Steinert et al. 2014). Sponge associated bacteria have been also frequently described as producers of bioactive natural products (Blunt et al. 2011; Blunt et al. 2012; Blunt et al. 2013). These communities include amongst other Actinobacteria also *Salinispora* and related strains (Hetschel et al. 2002).

Isolation of marine Actinobacteria

To date, the most common sources for the isolation of marine Actinobacteria are sediments and sponges. However, as mentioned above, Actinobacteria were found almost everywhere in the marine environment. Because of the large amount of bacteria living in the marine sediment (10^9 bacteria per mL, Fenical & Jensen 2006), the cells have to be separated using diverse dilution or stamp techniques.

The common method for the isolation of Actinobacteria is very similar to the methods used to isolate terrestrial ones. On the one hand, sea mud can be directly spread over the agar media (Okami et. al. 1972) or the sediment samples may be diluted and treated with diverse methods as described below.

Some sediment samples were mixed with sterile sea water (Jensen et al. 1991; Mincer et al. 2002) or used as dried samples (Takizawa *et al.* 1993) before they were heated up between 6 and 60min (Mincer et al. 2002; Jensen et al. 1991, Takizawa et al. 1993) at about 50°C. This heat-shock treatment should dispatch most non-spore forming bacteria to provide the slow growing Actinobacteria a selective benefit for growth. Such measures had to be taken to avoid that, as described in the concurrent paper of Karwehl and Stadler (2016) for fungi, the fast-growing strains in soil samples would inadvertently overgrow the more interesting, hitherto unexploited ones. Afterwards, the samples were diluted in several dilution steps and plated on different types of nutrient rich agar plates. Pathomaree et al. (2006) used sterile saline solution (Ringer's solution) to pre-incubate the sediment samples for 30 min before the dilution and the following inoculation on a range of different media and an incubation temperature of 55°C for the isolation of new thermophilic Actinobacteria taxa.

Another dilution technique was described by Mincer et al. (2002) for the isolation of the first *Salinispora* species. In this study, in addition to the heat shock dilution series approach, the wet sediment was air dried and afterwards pressed into a sterile form plug. This plug was used as a stamp to inoculate the agar plates by stamping the plug several times in a circular fashion onto the plate to cause a dilution of the sediment. This approach was used with and without a previously described heat-shock treatment.

For the isolation of "novel marine-derived Actinobacteria taxa" Magarvey et al. (2004) used a modification of the medium Stan21, which is normally used to isolate Myxobacteria from soil samples (Shimkets et al. 2004). Therefore, the yeast extract was eliminated and the distilled water was replaced by artificial sea water. After the media preparation and the addition of cycloheximide, filter paper disks were placed on agar and the wet sediment was spotted on the surface of the cellulose. The plates were incubated afterwards for 30 to 90 days at 30°C in a humidified chamber. With this method they isolated some unknown marine Actinobacteria which cluster between the *Salinispora* clade and the genus *Micromonospora*.

One possibility for the isolation of marine Actinobacteria out of seawater is a simple filter technique. Okami et al. (1972) described a method by which the seawater was centrifuged and filtered through a 0.3µl pore size filter. The concentrated microorganisms on the filter were afterwards suspended in filtered sea water and plated on different isolation media.

To isolate Actinobacteria out of sponges several approaches are described. In classical isolation techniques, the sponge samples were directly stamped on isolation media or in the dilution series method, sponge samples are crashed with a mortar, placed into sea water and after sedimentation, plated in different dilutions on specific sponge isolation agar (Mantalvo et al. 2005; Jiang et al. 2007). However, there are also some modifications of this method. Abdelmohsen et al. (2010) added the supernatant of crashed sponges (sponge extract) into the isolation media to rebuilt the natural environment. A further approach is the addition of both, "aqueous extract" like described before and "organic extract" where the sponge tissue was extracted with the help of hexane, dichlormethane and methanol. Finally, both studies demonstrated an enhanced number of novel isolated strains (Webster & Hill 2001; Selvin et al. 2004; Abdelmohsen et al. 2010). However, for all of these approaches, the sponges had to be harvested. To keep the sponges alive, Steinert et al. (2014) constructed a so called diffusion growth chamber (DGC). This chamber was build out of two combined centrifuge microfilter sections and was inoculated with different types of media. The media compositions differed in the amount of nutrients. Furthermore, every medium includes a small

amount of sponge homogenate which was prepared out of a homogenised sponge sample in sterile sea water. After inoculation, the DGCs were directly inserted in the living sponge and retaken after 4 weeks of incubation (Fig. 2). Subsequently, one part of the inoculated media was plated on isolation media and the other part was used to inoculate new DGCs which were inserted into the same sponges. In this study, the authors showed that they were able to detect and cultivate more bacteria than using the classical direct plating method while the sponges stayed in their natural environment.

Figure 2: Diffusion growth chamber (DGC) for in vivo cultivation of sponge-associated bacteria. Build-up of DGC out of two combined centrifuge microfilter sections with diffusible membranes (DM), inoculated with different types of media within the chamber (AC) and the plastic holder (H) for fixing within the sponge.

Most of the isolation media contained fungicidal agents like cycloheximide and nystatin to reduce fungal contamination as well as rifampicin and nalidixic acid to dispatch fast growing Gram-negative bacteria. All plates were incubated between 2 and 6 weeks between room temperature and 28°C.

Bioactive substances produced by marine Actinobacteria

While we concentrate in this review on the bioactive secondary metabolites like antibiotics, cytotoxic agents and fungicides, other biotechnological applications of marine Actinobacteria are the production of melanins, enzymes, enzyme inhibitors, single cell proteins as well as probiotics in aquaculture (Manivasagan et al. 2013).

Novel metabolites isolated from marine Actinobacteria include the antitumor agents chromomycins B, A2 and A3 from *Streptomyces coelicolor* (Lu et al., 2012), the antibacterial frigocyclinone from *Streptomyces griseus* (Brutner et al. 2005), the antifungal and anticancer agents, daryamides from *Streptomyces* sp. (Silvakumar et al. 2007) and further ones as listed in Table 1. However, it becomes apparent that most of the producer strains were classified as *Streptomyces* species, which are common terrestrial bacteria. To date, “real new structures” were only isolated from the two genera of genuine marine Actinobacteria *Salinispora* and *Marinospora* (Manivasagan et al. 2013). Salinosporamides A and B (Fig. 3) are both produced by *Salinispora tropica*. These compounds are

β -lactone- γ -lactams produced by a mixed PKS/NRPS biosynthesis. Salinosporamide A is an orally active proteasome inhibitor that induced apoptosis in multiple myeloma cells with mechanisms distinct from the commercial proteasome inhibitor anticancer drug Bortezomib (Chauhan et al. 2005). As NPI-0052, salinosporamide A entered as the first compound isolated out of an obligate marine organism, the clinical studies in multiple phase I trials for solid tumors, lymphoma and multiple myeloma (<http://www.nereuspharm.com/NPI-0052.shtml>). The second compound, salinisporamide B, differs only in a lack of chlorine and the subsequently less activity by a factor of 500 (Manivasagan et al. 2013). However, the terrestrial *Streptomyces* strain JS360 is the producer strain of the cinnabaramides A-G which are structurally close related to salinosporamide A (Stadler et al. 2007). These substances are also described as strong proteasome inhibitors however, Rachid et al. (2011) detected a significantly weaker cytotoxic effect than caused by salinosporamide A. Other unprecedented substances produced by *Salinispora tropica* are sporolide A, arenicolide A, cyanosporaside A and salinipyron A (Fig. 3). Even though, the salinipyrones A and B (Fig. 3) were first isolated out of the obligate marine Actinobacterium *Salinispora pacifica* (Oh et al. 2008). Both substances did not show antibiotic activity against drug resistance human pathogens, however a moderate cytotoxic activity was detected (Jensen et al. 2007; Manivasagan et al. 2013). Marinomycin A (Fig. 3), produced by a *Marinophilus* strain (Kwon et al. 2006), is a new polyene macrolide with a high toxicity to tumor cells and antibiotic effect against vancomycin - resistant *Enterococcus faecium* and methicillin – resistant *Staphylococcus aureus*.

Figure 3: Examples of new bioactive compounds and their corresponding structures produced by novel genera of marine Actinobacteria.

In conclusion, the discovery of the new marine Actinobacteria genera *Salinispora* and *Marinophilus* could be directly correlated to the new and unprecedented compounds with new structures and partially new modes of action. Like described before, molecular studies indicate a great potential for the isolation of novel genera of marine Actinobacteria. However, new isolation techniques will have

to be established and unexplored environments have to be sampled to avoid re-isolations of bacteria out of known genera producing common compounds.

Table 1: Examples of secondary metabolites produced by marine Actinobacteria

Compound	Biological activity	Species/Isolate	Reference
1,8-Dihydroxy-2-ethyl-3-methylantraquinone	Anticancer	<i>Streptomyces</i> sp.	Huang et al. (2006)
1-Hydroxy-1-norresistomycin	Antibacterial; anticancer	<i>Streptomyces chinaensis</i>	Gorajana et al. (2005) and Kock et al. (2005)
2-Allyloxyphenol	Antimicrobial; food preservative; oral disinfectant	<i>Streptomyces</i> sp.	Arumugam et al. (2010)
Abyssomycin C	Antibacterial (inhibition of PABA biosynthesis)	<i>Verrucospora maris</i>	Bister et al. (2004)
Albidopyrone	Anticancer	<i>Streptomyces</i> sp.	Hohmann et al. (2009a)
Antracyclines	Anticancer	<i>Streptomyces galileus</i>	Fujii and Ebizuka (1997)
Arenicolides A-C	Mild anticancer activity	<i>Salinispora arenicola</i>	Jensen et al. (2007)
Arenimycin	Antibacterial; anticancer	<i>Salinispora arenicola</i>	Asolkar et al. (2006)
Aureoverticillactam	Anticancer	<i>Streptomyces aureoverticillatus</i>	Mitchell et al. (2004)
Avermectin	Antiparasitic	<i>Streptomyces avermitilis</i>	Burg et al. (1979)
Bafilomycin	ATPase-inhibitor of micro-organisms, plant and animal cells	<i>Streptomyces griseus</i> , <i>Streptomyces halstedii</i>	Werner et al. (1984) and Frändberg et al. (2000)
Bisanthraquinone	Antibacterial	<i>Streptomyces</i> sp.	Socha et al. (2006)
Butenolides	Anticancer	<i>Streptoverticillium luteoverticillatum</i>	Lie et al. (2006)
Carboxamycin	Antibacterial; anticancer	<i>Streptomyces</i> sp.	Hohmann et al. (2009b)
Chinikomycins	Anticancer	<i>Streptomyces</i> sp.	Lie et al. (2005)
Chlaramphenicol	Antibacterial, inhibitor of protein biosynthesis	<i>Streptomyces venusoelae</i>	Bewick et al. (1976)
Chlorodihydroquinones	Antibacterial; anticancer	Novel actinomycete	Soria-Mercado et al. (2005)
Cyanospraside A	Unknown	<i>Salinispora pacifica</i>	Jensen et al. (2007)
Cyclomarines	Antiinflammatory	<i>Streptomyces</i> sp., <i>Salinispora arenicola</i>	Schultz et al. (2008)
Daryamides	Antifungal; anticancer	<i>Streptomyces</i> sp.	Sivakumar et al. (2007)
Dermacozines	Anticancer, radical scavenging	<i>Dermacoccus</i> sp.	Abdel-Mageed et al. (2010)
Diazepinomicin	Anticancer	<i>Micromonospora</i> sp.	Charan et al. (2004)
Enterocin	Bacteriostatic	<i>Streptomyces maritimus</i>	J. Piel, Max-Planck Inst., Jena (2000)
Essramycin	Antibacterial	<i>Streptomyces</i> sp.	El-Gendy et al. (2008)
Frigocyclinone	Antibacterial	<i>Streptomyces griseus</i>	Bruntner et al. (2005)
Glaciapyrroles	Antibacterial	<i>Streptomyces</i> sp.	Macherla et al. (2005)
Hygromycin	Antimicrobial, immunosuppressive	<i>Streptomyces hygroscopicus</i>	Omura et al. (1987), Uyeda et al. (2001)
Lajollamycin	Antibacterial	<i>Streptomyces nodosus</i>	Manam et al. (2005)
Lincomycin	Antibacterial, inhibitor of protein biosynthesis	<i>Streptomyces lincolnensis</i>	Peschke et al. (2006)
Lynamicins	Antibacterial	<i>Marinispora</i> sp.	McArthur et al. (2008)
Mansouramycins	Anticancer	<i>Streptomyces</i> sp.	Hawas et al. (2009)
Marinomycin A-D	Antimicrobial, anticancer	<i>Marinispora</i>	Kwon et al. (2006)
Mechercharmycins	Anticancer	<i>Thermoactinomyces</i> sp.	Kanoh et al. (2005)
Mitomycin C	Anticancer, binds to double stranded DNA	<i>Streptomyces lavendulae</i>	Mao et al. (1999)
ML-449	Anticancer	<i>Streptomyces</i> sp.	Jørgensen et al. (2010)

Pacificanones A&B	Antibacterial	<i>Salinispora pacifica</i>	Oh et al. (2008)
Piericidins	Anticancer	<i>Streptomyces</i> sp.	Hayakawa et al. (2007)
Proximicins	Antibacterial; anticancer	<i>Verrucosisspora</i> sp.	Fiedler et al. (2008)
Rapamycin	Immunosuppressive, antifungal	<i>Streptomyces hygroscopicus</i>	Vezina et al. (1975)
Resistoflavin methyl ester	Antibacterial; anti-oxidative	<i>Streptomyces</i> sp.	Kock et al. (2005)
Salinamides	Antiinflammatory	<i>Streptomyces</i> sp.	Moore et al. (1999)
Saliniketal	Cancer chemoprevention	<i>Salinispora arenicola</i>	Jensen et al. (2007)
Salinispyrone	Unknown	<i>Salinispora pacifica</i>	Jensen et al. (2007)
Salinispyrone A&B	Mild anticancer activity	<i>Salinispora pacifica</i>	Oh et al. (2008)
Salinosporamide A	Anticancer; antimalarial	<i>Salinispora tropica</i>	Jensen et al. (2007) and Prudhomme et al. (2008)
Salinosporamide B&C	Anticancer	<i>Salinispora tropica</i>	Williams et al. (2005)
Sesquiterpene	Unknown	<i>Streptomyces</i> sp.	Wu et al. (2006)
Staurosporine	Antitumor; phycotoxicity	<i>Streptomyces</i> sp.	Wu et al. (2006)
Streptokordin	Antitumor	<i>Streptomyces</i> sp.	Jeong et al. (2006)
Streptomycin	Antimicrobial	<i>Streptomyces griseus</i>	Egan et al. (1998)
Streptozotocin	Diabetogenic	<i>Streptomyces achromogenes</i>	Herr et al. (1967)
Tetracyclines	Antimicrobial	<i>Streptomyces achromogenes</i> , <i>Streptomyces rimosus</i>	Saleh et al. (1985) and Hansen et al. (2001)
Thiocoraline	Anticancer	<i>Micromonospora</i> spp.	Perez Baz et al. (1997)
Tirandamycins	Antibacterial	<i>Streptomyces</i> sp.	Carlson et al. (2009)
TP-1161	Antibacterial (inhibition of protein synthesis)	<i>Nocardopsis</i> sp.	Engelhardt et al. (2010)
Valinomycin	Isophor, toxic for Pro- and Eukaryotes	<i>Streptomyces griseus</i>	Andersson et al. (1998)
ZHD-0501	Anticancer	<i>Actinomadura</i> sp.	Han et al. (2003)
Elaiomycins B and C	Anticancer	<i>Streptomyces</i> sp. BK 190	Helaly et al. (2011)
N-(2-hydroxyphenyl)-2phenazinamine (NHP)	Anticancer, antifungal	<i>Nocardia dassonvillei</i>	Gao et al. (2012)

2 Myxobacteria – the underestimated bacterial resource

2.1. History of myxobacteria

The first myxobacterium was discovered in 1809 by the German botanist H.F. Link and named *Polyangium vitellinum*, but erroneously it was characterized as fungus because of the characteristic fungi-like life cycle (Link 1809). It took many years, until 1892, until Roland Thaxter identified these organisms as bacteria (Thaxter 1892). Actually, the order of Myxococcales consists of 55 species including 28 genera (fig. 4) and differentiates from other Gram-negative prokaryotes by the mutuality to have a special life cycle.

Figure 4 Current taxonomy of the order Myxococcales

Myxobacteria belong to the δ -subgroup of proteobacteria and therefore are Gram-negative. The vegetative cells are rod-shaped with the ability to glide over solid surfaces and form some kind of multicellular, species-specific “fruiting-bodies” under starvation conditions without access to a sufficient nutrient storage (Reichenbach et al. 1988) (fig. 5). Those fruiting bodies can comprise up to 10^5 individuals and show a wide range of differences between the genera and species referring their height, shape and color, which mostly varies from yellow, orange or red until brown or even black (Reichenbach et al. 1983, Garcia and Müller 2014).

Figure 5 A: Fruiting bodies of *Stigmatella aurantiaca* (bar = 1000 µm); B: Cells of *Myxococcus virescens* (bar = 50 µm); C: Swarming of *Corallococcus coralloides* (bar = 5000 µm)

Within the fruiting bodies, the vegetative cells transform to short, so called myxospores, often enclosed in sporangioles. Because of desiccation resistance, myxospores are able to survive in unfavorable environmental conditions for many years (Reichenbach et al. 2006). Myxobacteria can be found in large populations on many substrates in nature all over the world, e.g. soil, rotting wood and other habitats. Due to their nutritional requirements, myxobacteria can be divided into two ecological groups that are also in agreement with their phylogeny. Predators use other bacteria or yeasts as food source, and cellulose decomposers, belonging to the genera *Sorangium* and *Byssovorax* decompose organic materials by producing different types of lytic exoenzymes (Reichenbach et al. 1988; Reichenbach et al. 2006).

Another important and interesting feature of myxobacteria is their ability to produce a broad range of structurally diverse secondary metabolites, many of them with bioactivity. The working group Microbial Strain Collection at the Helmholtz-Center for Infection Research (HZI) in Braunschweig, has the largest collection of myxobacteria worldwide with more than 9000 strains, including all validly described type strains (fig 6).

Figure 7 Percentage of genera in the producers of our novel secondary metabolites from myxobacteria (modified according to Gerth et al. 2003)

2.2. Isolation methods

To find new bioactive substances, it seems reasonable to exploit new producer organisms and insert these novel species and genera in the latest taxonomic classification (Müller and Wink 2014). It is necessary to use basic routine methods (Dawid 2000, Shimkets et al. 2006) as well as new approaches (Garcia 2009, Mohr et al. 2015) for the isolation and cultivation of potential and interesting new producer strains.

In general, myxobacteria are characterized as mesophilic soil organisms which prefer a temperature of 30° and a neutral pH. Nevertheless, also acidophilic (Brockmann and Boyd 1963), alkaliphilic (Hook 1977) and psychrophilic (Dawid et al. 1988) species were found in the last decades, demonstrating the enormous adaptability of myxobacteria even to extreme uncomfortable habitats. Myxobacteria can also be found in marine, saline habitats, for example *Haliangium ochraceum* and *Haliangium tepidum* (Iizuka et al. 1998). To isolate new myxobacterial strains from different biotopes, environmental samples (e.g. soil, sand, dead wood, bark, leaves, compost) were treated by a standardized procedure. For soil samples, an amount of 50-150g of sample is collected in 1-5 cm depth below the surface in sterile vials. Before the enrichment on different plates, the sample has to be air dried and characterized concerning different parameters like color, size, grain, content and acidity (Dawid 2000). Commonly, different types of plates are used for the enrichment of a wide range especially of myxobacteria species referring to the methods of Shimkets et al. 2006. Living *E. coli* cells on water agar are suitable as the feed organism for predatory myxobacteria (Shimkets et al. 2006). Many soil

bacteria are able to degrade dead, but not living, microorganisms. Furthermore, most soil bacteria grow faster than myxobacteria. By using living bait organisms, myxobacteria have an advantage in comparison to other, not or less swarming, competitors (Garcia 2009). To enrich and isolate specifically cellulose degrading myxobacteria, mineral salt agar Stan 21 is used. Sterile filter paper is placed on the top of the agar and serve as food source (Shimkets et al. 2006). The plates are normally incubated at 30° over a period of several weeks, until the visually striking myxobacteria can be seen with the naked eye. The following isolation, purification and identification of new strains is carried out on VY/2 plates, containing yeast as nutrient source (Dawid 2000). It is supposed, that the preparation of the medium, combining the important characteristics like in the natural habitats of myxobacteria, leads to high advantage finding novel strains. For example, novel strains were isolated by growing at room temperature (23°) as well as under white light or sun light exposure and on acidic or saline agar plates (Mohr et al. 2015, Garcia 2009). The identification of the facultative anaerobic genus *Anaeromyxobacter* (Sanford et al. 2002) leads to the assumption, that different air conditions tried within the isolation procedures can reveal facultative anaerobic and microaerophilic species (Garcia 2009). Culture-independent methods, like clone bank analyzes, revealed that there is a high number of new potential producer species (Mohr et al. 2015). The development of new cultivation methods is important to find the best growth conditions for all these different types of uncultivated myxobacteria .

The procedure of the standardized screening method, developed at the HZI, starts with the cultivation of a new isolated strain in different liquid complete media (each 100ml) with different C- and N-sources. The bacteria are cultivated at 30 °C and shaking (180 rpm) 7-14 days. Myxobacteria secrete the secondary metabolites out of the cells into their environment, in this case into the medium. To bind the metabolites and thereby preventing a feedback inhibition or a degradation of the metabolite by a producer strain, XAD16 adsorber resin is added to the culture. After sieving, the resin and the adsorbed compounds are extracted with acetone, evaporated and finally eluted with methanol, resulting in a raw extract of a 1:100 concentration which is used for further analyzes (Reichenbach et al. 1993). However, it is necessary to find the best growth conditions and to optimize the specific production rate for each producer strain, as well as an economic justifiable fermentation process has to be established.

To investigate the effect of a crude extract from a new potential myxobacterial producer strain against different pathogens with clinical importance and to find the active principle, the working group Microbial Strain Collection at the HZI use a dereplication system, which is a combination of a biological activity assay and a chemical screening with liquid chromatography-high resolution mass spectrometry (LC/HRMS). First, the minimum inhibitory concentration (MIC) of the extract is determined by the use of a microtiter plate based serial dilution assay containing different Gram-positive and Gram-negative bacteria as well as fungi to assess selectivity. After semipreparative high performance liquid chromatography (HPLC), the inhibitory effect of the fractionated extract is examined against the affected organisms and further analyzed by ultra-high resolution-time of flight mass spectrometry (UHR-TOF-MS) regarding molecular masses and molecular formulae (fig. 8). These obtained molecular features are matched against known myxobacterial compounds from the in-house database (Myxobase) or Dictionary of Natural Products (Taylor and Francis, 2016). The strategy consisting of

the use of the different methods above gives possibilities to find and identify new bioactive substances from myxobacteria.

Figure 8 Combination of activity assay and HPLC-MS

2.3. Genetical potential

The genomes of myxobacteria belong to the largest ever found in bacteria. The genome of the *Sorangium* strain So ce56, for example, consists of more than 13.000 base pairs and includes seventeen secondary metabolite gene clusters (Schneikert et al. 2007) and the genome of *M. xanthus* comprises at least around 9000 base pairs (Goldmann et al. 2006). It is suggested that this large genome size is connected to the extraordinary and complex life cycle of myxobacteria. In contrast to other bacteria, they need a much more complex genetic constitution to demonstrate their special social behavior including swarming and culminating fruiting bodies. Within these enormously large genomes, there probably exists a high capacity concerning to the unlimited number of unknown and promising secondary metabolites (Wenzel and Müller 2009).

It is hardly possible to figure out the potential of a strain to produce bioactive substances only by phenotypic and biochemic analyzes, because some metabolites cannot be detected due to the applied extraction and detection methods (Wenzel and Müller 2009). Therefore, our research is focusing on the discovery of biosynthetic pathways and the connected gene clusters of novel, potentially anti-infective natural compounds as well as the full genome sequences of scientific interesting bacteria strains. With this information, it might become easier to find possibilities for enhancing the production

of known metabolites as well as activating unused “silent” genes for novel substances (Müller and Wink 2014). The genome mining approach is based on the genome sequences, which are used to predict synthesized compounds with the help of bioinformatics analyzes. The recovered genetic information can lead to specific inducing of the supposed biosynthetic gene clusters that encode for new bioactive products (Müller and Wink 2014).

2.5. Pharmaceutically important secondary metabolites

Myxobacteria are a rich source of novel and unique secondary metabolites, mainly polyketides and nonribosomal polypeptides. Many of these metabolites show antibiotic activities and are urgently needed as new drugs for a broad range of applications. These skills probably evolved because of the natural competition between different kinds of organisms in varying habitats. For example, the cellulose degrading members of the genus *Sorangium* have to combat other cellulose degraders sharing the same habitat like fungi which also use wood (cellulose) as nutrient source, whereas proteolytic myxobacteria need to stand up to other degraders of decaying organic material (Gerth et al. 2003). The existence of a link between the production of biological active secondary metabolites and microbial predation is supposed, because about 20% of the known myxobacterial compounds show antibiotic effects. The importance of secondary metabolites derived from natural producers should not be underestimated, because they are the source of almost 50% of most important medications for humans (Demain 1999).

The scientific interest for myxobacteria increased already in the year 1947, when it was shown that a strain of *Myxococcus virescens* has a significant inhibitory effect on the growth of *Staphylococcus aureus* (Oxford 1947). In the following years many research groups all over the world tried to find the active compounds by optimizing the growth conditions. It was believed for a long time that it is very difficult to cultivate myxobacteria in liquid media and that these organisms are somewhat problematic with regard to their axenic growth in general (Reichenbach et al. 1993). The breakthrough in discovering antibiotic substances from myxobacteria happened in 1977 by elucidation of the complete chemical structure of the potent antifungal secondary metabolite ambruticin, produced by *Sorangium cellulosum* (Connor et al. 1977; Ringel et al. 1977). Next to the use as antibiotic or antifungal drug, biologically active secondary metabolites can also be used as antiparasitic, antiviral and antitumor drugs in human and veterinary medicine and also as insecticides, acaricides and herbicides. They can act e.g. as inhibitors of carboxylases, polymerases or mitochondrial respiration as well as inhibitors of eukaryotic protein synthesis (Weissman and Müller 2009). Furthermore, also antidiabetic, antimalarial, antihypertensive, antihypercholesterolemic, insuline-sensitizing and immunoregulatory characteristics can be attributed to microbial products (Grabley and Thiericke 1999, Schreurs et al. 2009, Berod et al. 2014). A molecule with biological effects can also work as a model for a synthetic production to get a higher output under better economic conditions (Reichenbach et al. 1993). More than 100 new and important myxobacterial core structures have been discovered (Garcia 2009), some of them are summarized in table 2. Another important ability of myxobacteria is the production of polyunsaturated fatty acids (PUFAs) like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which play an

important role in food industry and for pharmaceutical applications (Garcia 2011, Gemperlein et al. 2016).

Furthermore, the natural compounds can also work as a basic structure for chemical modifications which can lead to an exploitation in the pharmaceutical area. Epothilones A and B, for example, were originally found in a *Sorangium cellulosum* strain and are distinguished by antifungal and cytotoxic activity (Gerth et al. 1996). Meanwhile, there are modified versions of these molecules already used in the active treatment against different types of cancer or are present in clinical trials. Until epothilones were discovered, the common medication for advanced and early-stage breast cancer were taxanes, anthracyclines and capecetabine, but these agents are often subjected to a multidrug-resistance, which has a natural origin in the patient. It is suggested that there is an overexpression of efflux pumps and other proteins serving as efflux pumps, so that the anticancer agents can be removed very easy out of the targeted cancer cell (Egerton 2008). In fact, this resistance limits dramatically the chances of success within a therapy (Burger 2003). As an effective alternative to the chemotherapies with taxanes and anthracyclines, the semi-synthetic epothilone derivative ixabepilone (Ixempra®) was developed in October 2007 for monotherapie of different stages of breast cancer (fig. 9) (Reichenbach and Höfle 2008). In contrast to the other available pharmaceuticals referring to this disease, ixabepilone is just low affected by multidrug-resistant mechanisms and consequently offers a chance to eliminate the tumor cells effectively (Pivot et al. 2007).

Figure 9 Chemical structures of epothilon B and ixabepilon

Table 2: Important compounds and their biological activity found in myxobacteria

compound	activity	mode of action	species	reference
ambruticin	antifungal	Interfere with high-osmolarity glycerol (HOG) signaling pathway	<i>S. cellulosum</i>	Ringel et al. (1977); Connor et al. (1977)
aurachins	antibacterial	block NADH oxidation	<i>S. aurantiaca</i>	Kunze et al. (1987)
chrondramide	antifungal/ cytostatic	Interfere with actine polymerisation	<i>C. crocatus</i>	Kunze et al. (1995)
crocacin	antibacterial	Inhibits electron transport	<i>C. crocatus</i>	Kunze et al. (1994)
cystobactamids	antibacterial	Inhibit type II topoisomerase	<i>Cystobacter</i> sp.	Baumann et al. (2014)
cystothiazol	antifungal/	inhibits submitochondrial	<i>C. fuscus</i>	Ojika et al. (1998)

	cytostatic	NADH oxidation		
disciformycins	antibacterial	n/a	<i>P. fallax</i>	Surup et al. (2014)
epothilones	cytotoxic	Inhibition of microtubule function	<i>S. cellulorum</i>	Gerth et al. (1996)
etnangien	antibacterial	Inhibits nucleic acid polymerases	<i>S. cellulorum</i>	Irschik et al. (2007)
melithiazols	antibacterial	inhibit NADH oxidation	<i>M. lichenicola</i> , <i>A. gephyra</i> , <i>M. stipitatus</i>	Sasse et al. (1999)
myxothiazol	antifungal	Inhibits electron transport	<i>M. fulvus</i>	Gerth et al. (1980)
myxovalargin	antibacterial	Inhibits of protein synthesis and damages cell membranes	<i>M. fulvus</i>	Irschik et al. (1983) Irschik et al. (1985)
myxovirescin	antibacterial	Inhibition of signal peptidase	<i>M. virescens</i>	Gerth et al. (1982)
rhizopodin	cytostatic	Alteration of protein phosphorylation	<i>M. stipitatus</i>	Sasse et al. (1993)
ripostatin	antibacterial	Inhibits RNA polymerase	<i>S. cellulorum</i>	Irschik et al. (1995)
sorangicin	antibacterial	Inhibits RNA polymerase	<i>S. cellulorum</i>	Irschik et al. (1987)
soraphens	antifungal, antiviral, cancerocidal, immuno-regulatory, insulin-sensitizing	Inhibit acetyl-CoA carboxylase	<i>S. cellulorum</i>	Gerth et al. (1994) Schreurs et al. (2009) Martinez et al. (2013) Berod et al. (2014) Corominas-Faja et al. (2014) Koutsoudakis et al. (2015)
stigmatellin	antibacterial	Inhibits electron transport	<i>S. aurantiaca</i>	Kunze et al. (1994)

References

Abdel-Mageed WM, Milne BF, Wagner M, Schumacher M, Sandor P, Pathom-aree W, Goodfellow M, Bull AT, Horikoshi K, Ebel R, Diederich M, Fiedler HP, Jaspars M (2010) Dermacozines, a new phenazine family from deep-sea dermacocci isolated from a Mariana Trench sediment. *Org Biomol Chem* 8: 2352–2362.

Abdelmohsen UR, Pimentel-Elardo SM, Hanora A, Radwan M, Abou-El-Ela SH, Ahmed S, Hentschel U (2010) Isolation, phylogenetic analysis and anti-infective activity screening of marine sponge-associated actinomycetes. *Mar Drugs* 8: 399–412.

Andersson M, Mikkola R, Kroppenstedt R, Rainey F, Peltola J, Helin J, et al. (1998) The mitochondrial toxin produced by *Streptomyces griseus* strains isolated from an indoor environment is valinomycin. *Appl Environ Microbiol* 64: 4767–4773.

Arumugam M, Mitra A, Jaisankar P, Dasgupta S, Sen T, Gachhui R, et al. (2010) Isolation of an unusual metabolite 2-allyloxyphenol from a marine actinobacterium, its biological activities and applications. *Appl Microbiol Biotechnol* 86: 109–117.

Asolkar RN, Jensen PR, Kauffman CA, Fenical W, Daryamides AC (2006) Weakly cytotoxic polyketides from a marine-derived actinomycete of the genus *Streptomyces* strain CNQ-085. *J Nat Prod* 69: 1756–1759.

[Baumann S](#), [Herrmann J](#), [Raju R](#), [Steinmetz H](#), [Mohr KI](#), [Hüttel S](#), [Harmrolfs K](#), [Stadler M](#), [Müller R](#) (2014) Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity [Angew Chem Int Ed Engl](#) 53: 14605-14609.

[Berod L](#), [Friedrich C](#), [Nandan A](#), [Freitag J](#), [Hagemann S](#), [Harmrolfs K](#), [Sandouk A](#), [Hesse C](#), [Castro CN](#), [Bähre H](#), [Tschirner SK](#), [Gorinski N](#), [Gohmert M](#), [Mayer CT](#), [Huehn J](#), [Ponimaskin E](#), [Abraham WR](#), [Müller R](#), [Lochner M](#), [Sparwasser T](#) (2014) De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. [Nat Med](#) 20: 1327-1333.

Bewick M, Williams S, Veltkamp C (1976) Growth and ultrastructure of *Streptomyces venezuelae* during chloramphenicol production. *Microbios* 16: 191–199.

Bister B, Bischoff D, Ströbele M, Riedlinger J, Reicke A, Wolter F, Bull AT, Zähler H, Fiedler HP, Süssmuth RD (2004) Abyssomicin C-A - polycyclic antibiotic from a marine *Verrucospora* strain as an inhibitor of the p-aminobenzoic acid/tetrahydrofolate biosynthesis pathway. *Angew Chem Int Ed Engl* 43: 2574–2576.

Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT, Prinsep MR (2007) Marine natural products. *Nat Prod Rep* 24:31–86.

Blunt J W, Copp BR, Munro MHG, Northcote PT, Prinsep MR (2011) Marine natural products. *Nat Prod Rep* 28: 196–268.

Blunt JW, Copp BR, Keyzers R A, Munro MHG, Prinsep MR (2012) Marine natural products. *Nat Prod Rep* 29: 144–222.

Blunt JW, Copp BR, Keyzers R A, Munro MHG, Prinsep MR (2013) Marine natural products. *Nat Prod Rep* 30: 237–323.

Brockman ER and Boyd WL (1963) Myxobacteria from soils of the Alaskan and Canadian Arctic, *J Bacteriol* 86: 605-606.

Bruntner C, Binder T, Pathom-aree W, Goodfellow M, Bull AT, Potterat O, et al. (2005) Frigocyclinone, a novel angucyclinone antibiotic produced by a *Streptomyces griseus* strain from Antarctica. *J Antibiot* 58: 346–349.

Bull AT (2011) Actinobacteria of the extremobiosphere. In: *Extremophiles handbook* (pp.1203-1240) Ed Horikoshi K. Springer.

Bull AT, Starch JEM (2007) Marine actinobacteria: new opportunities for natural product search and discovery. *Trends in Microbiol* 15: 491-499.

Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, et al. (1997) Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. *Antimicrob Agents Chemother* 15: 361–367.

[Burger H](#), [Foekens JA](#), [Look MP](#), [Meijer-van Gelder ME](#), [Klijn JG](#), [Wiemer EA](#), [Stoter G](#), [Nooter K](#). (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. *Clin Cancer Res* 9: 827-836.

Carlson JC, Li S, Burr DA, Sherman DH (2009) Isolation and characterization of tirandamycins from a marine-derived *Streptomyces* sp. *J Nat Prod* 72: 2076–2079.

Charan RD, Schlingmann G, Janso J, Bernan V, Feng X, Carter GT (2004) Diazepinomicin, a new antimicrobial alkaloid from a marine *Micromonospora* sp. *J Nat Prod* 67: 1431–1433.

Chau R, Kalaitzis JA, Neilan BA (2011) On the origins and biosynthesis of tetrodotoxin. *Aqua Toxicol* 104: 61-72.

Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. *Cancer Cell* 8: 407–419.

Connor DT, Greenough RC, Strandtmann M (1977) W-7783, a unique antifungal antibiotic. *J Org Chem* 42: 3664-3669.

[Corominas-Faja B](#), [Cuyàs E](#), [Gumuzio J](#), [Bosch-Barrera J](#), [Leis O](#), [Martin ÁG](#), [Menendez JA](#) (2014) Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells, [Oncotarget](#) 5: 8306-8316.

Dawid W (1978) Fruchtkörperbildene Myxobakterien in Böden Brasiliens. *Z Allg Mikrobiol* 34: 333-335.

Dawid W, Gallikowski CA, Hirsch, P (1988): 3.8 Psychrophilic myxobacteria from antarctic soils, *Polarforschung*, Bremerhaven, Alfred Wegener Institute for Polar and Marine Research & German Society of Polar Research, 58: 271-278.

Demain A, Pharmaceutically active secondary metabolites of microorganisms (1999) *Appl Microbiol Biotechnol* 52: 455-463.

[Diez J](#), [Martinez JP](#), [Mestres J](#), [Sasse F](#), [Frank R](#), [Meyerhans A](#) (2012) Myxobacteria: natural pharmaceutical factories, [Microb Cell Fact](#) 11: 52.

Do H, Kogure K, Simidu U (1990) Identification of deep-sea-sediment bacteria which produce tetrodotoxin. *Appl Environ Microbiol* 56: 1162.

Do H, Kogure K, Imada C, Noguchi T, Ohwada K, Simidu U (1991) Tetrodotoxin production of actinomycetes isolated from marine sediment. *J Appl Microbiol* 70: 464-468.

[Egerton N](#) (2008) Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer. *P T* 33: 523-531.

Egan S, Wiener P, Kallifidas D, Wellington EMH (1998) Transfer of streptomycin biosynthesis gene clusters within streptomycetes isolated from soil. *Appl Environ Microbiol* 64: 5061–5063.

El-Gendy MM, Shaaban M, Shaaban KA, El-Bondkly AM, Laatsch H (2008). Essramycin: a first triazolopyrimidine antibiotic isolated from nature. *J Antibiot* 61: 149–157.

Engelhardt K, Degnes KF, Kemmler M, Bredholt H, Fjaervik E, Klinkenberg G, Sletta H, Ellingsen TE, Zotchev SB (2010). Production of a new thiopeptide antibiotic, TP-1161, by a marine *Nocardiopsis* species. *Appl Environ Microbiol* 76: 4969–4976.

Fenical W, Baden D, Burg M, de Goyet CV, Grimes JD, Katz M, Marcus NH, Pomponi S, Rhines P, Tester P, Vena J (1999) Marine derived pharmaceuticals and related bioactive compounds. In: *From Monsoons to Microbes: Understanding the Ocean's Role in Human Health*. (pp. 71-86) Ed. Fenical W. National Academies Press.

Fenical W, Jensen P (2006) Developing a new resource for drug discovery: marine actinomycete bacteria. *Nature Chem Biol* 2: 666-673.

Fiedler HP, Bruntner C, Riedlinger J, Bull AT, Knutsen G, Goodfellow M, Jones A, Maldonado L, Pathom-aree W, Beil W, Schneider K, Keller S, Sussmuth RD (2008) Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete *Verrucosisspora*. *J Antibiot* 61: 158–163.

Frändberg E, Petersson C, Lundgren LN, Schnürer J (2000) *Streptomyces halstedii* K122 produces the antifungal compounds bafilomycin B1 and C1. *Can J Microbiol* 46: 753–758.

Fujii I, Ebizuka Y. (1997) Anthracycline biosynthesis in *Streptomyces galilaeus*. *Chem Rev* 97: 2511-2524.

Gao X, Lu Y, Xing Y, Ma Y, Lu J, Bao W, Wang Y, Xi T (2012) A novel anticancer and antifungus phenazine derivative from a marine actinomycete BM-17. *Microbiol Res* 167: 616–622.

[Garcia RO](#), [Krug D](#), [Müller R](#). (2009) Chapter 3. Discovering natural products from myxobacteria with emphasis on rare producer strains in combination with improved analytical methods, [Methods Enzymol](#). 458:59-91.

Garcia R, Pistorius D, Stadler M, Müller R (2011) Fatty acid-related phylogeny of Myxobacteria as an approach to discover polyunsaturated omega-3/6 fatty acids. *J of Bacteriology* 139: 1930-1942.

Garcia RO and Müller R (2014) The Family Haliangiaceae In: The Prokaryotes Deltaproteobacteria and Epsilonproteobacteria (pp 173-181) Eds. Rosenberg E, DeLong EF, Lory S, Stackebrandt E, Thompson F, Springer

Garcia RO and Müller R (2014) The Family HaliangiaceaeThe Family Myxococcaceae In: The Prokaryotes Deltaproteobacteria and Epsilonproteobacteria (pp 192-212) Eds. Rosenberg E, DeLong EF, Lory S, Stackebrandt E, Thompson F, Springer

Garcia RO and Müller R (2014) The Family Nannocystaceae In: The Prokaryotes Deltaproteobacteria and Epsilonproteobacteria (pp 213-229) Eds. Rosenberg E, DeLong EF, Lory S, Stackebrandt E, Thompson F, Springer

Garcia RO and Müller R (2014) The Family Phaselicistaceae In: The Prokaryotes Deltaproteobacteria and Epsilonproteobacteria (pp 239-245) Eds. Rosenberg E, DeLong EF, Lory S, Stackebrandt E, Thompson F, Springer

Garcia RO and Müller R (2014) The Family Polyangiaceae In: The Prokaryotes Deltaproteobacteria and Epsilonproteobacteria (pp 247-279) Eds. Rosenberg E, DeLong EF, Lory S, Stackebrandt E, Thompson F, Springer

[Gemperlein K](#), [Zipf G](#), [Bernauer HS](#), [Müller R](#), [Wenzel SC](#) (2016) Metabolic engineering of *Pseudomonas putida* for production of docosahexaenoic acid based on a myxobacterial PUFA synthase. [Metab](#) 33: 98-108.

[Gerth K](#), [Irschik H](#), [Reichenbach H](#), [Trowitzsch W](#) (1980) Myxothiazol, an antibiotic from *Myxococcus fulvus* (myxobacterales). I. Cultivation, isolation, physico-chemical and biological properties. *J Antibiot* (Tokyo) 33: 1474-9.

Gerth K, Pradella S, Perlova O, Beyer S, Müller R (2003) Myxobacteria: proficient producers of novel natural products with various biological activities--past and future biotechnological aspects with the focus on the genus *Sorangium*. [J Biotechnol](#) 106: 233-53.

Gerth K, Ischik H, Reichenbach H, Trowitzsch WPG (1982), The myxovirescins, a family of antibiotics from *Myxococcus virescens* (myxobacterales). *J Antibiot* [35](#): 1454-1459.

Gerth K, Trowitzsch WPG, Schultze R, Lehmann J (1984) Inexpensive media for mass cultivation of myxobacteria. *Appl Microbiol Biotechnol* 19: 23-28.

Gerth K, Bedorf N, Irschik H, Höfle G, Reichenbach H (1994) The soraphens: a family of novel antifungal compounds from *Sorangium cellulosum* (Myxobacteria). I. Soraphen A1 alpha: fermentation, isolation, biological properties. *J Antibiot* [47](#): 23-31.

Gerth K, Bedorf N, Irschik H, Höfle G, Reichenbach H (1996) Epothilons A and B: antifungal and cytotoxic compounds from *Sorangium cellulosum* (myxobacteria) production, physico-chemical and biological properties. *J Antibiot* 49: 560-563.

Goldman BS, Niernan WC, Kaiser D, Slater SC, Durkin AS, Eisen JA, Ronning CM, Barbazuk WB, Blanchard M, Field C, Halling C, Hinkle G, Iartchuk O, Kim HS, Mackenzie C, Madupu R, Miller N, Shvartsbeyn A, Sullivan SA, Vaudin M, Wiegand R, Kaplan HB (2006) Evolution of sensory complexity recorded in a myxobacterial genome. *Proc Natl Acad Sci USA* 103: 15200-15205.

Goodfellow M, Haynes JA (1984) Actinomycetes in marine sediments. In: Biological, biochemical, and biomedical aspects of Actinomycetes (pp. 453-472). Eds Ortiz-Ortiz L, Bojalil LF, Yakoleff V. New York: Academic Press.

Gorajana A, Kurada BV, Peela S, Jangam P, Vinjamuri S, Poluri E, et al. (2005) 1-Hydroxy- 1-norresistomycin, a new cytotoxic compound from a marine actinomycete, *Streptomyces chibaensis* AUBN1/7. *J Antibiot* 58: 526–529.

Grabley S, Thiericke R (1999) The impact of natural products on drug discovery. *Drug discovery from nature*. Springer, 3-37.

Han SK, Nedashkovskaya OI, Mikhailov VV, Kim SB, Bae KS (2003) *Salinibacterium amurskyense* gen. nov., sp. nov., a novel genus of the family Microbacteriaceae from the marine environment. *Int J Syst Evol Microbiol* 53: 2061–2066.

Hansen LH, Ferrari B, Sørensen AH, Veal D, Sørensen S (2001) Detection of oxytetracycline production by *Streptomyces rimosus* in soil microcosmos by combining whole cell biosensors and flow cytometry. *Appl Environ Microbiol* 67: 239–244.

Hawas UW, Shaaban M, Shaaban KA, Speitling M, Maier A, Kelter G, Fiebig HH, Meiners M, Helmke E, Laatsch H (2009) Mansouramycins A–D, cytotoxic isoquinolinequinones from a marine streptomycete. *J Nat Prod* 72: 2120–2124.

Hayakawa Y, Shirasaki S, Shiba S, Kawasaki T, Matsuo Y, Adachi K, et al. (2007) Piericidins C7 and C8, new cytotoxic antibiotics produced by a marine *Streptomyces* sp. *J Antibiot* 60:196–200.

Helaly SE, Pesic A, Fiedler HP, Süßmuth RD (2011) Elaiomycins B and C: Alkylhydrazide antibiotics from *Streptomyces* sp. BK 190. *Org Lett* 13: 1052–1055.

Helmke E, Weyland H (1984) *Rhodococcus marinonascens* sp. nov., an actinomycete from the sea. *Int J Syst Bacteriol* 34:127-138.

Hentschel U, Hopke J, Horn M, Friedrich AB, Wagner M, Hacker J, Moore BS (2002) Molecular evidence for a uniform microbial community in sponges from different oceans. *Appl Environ Microbiol* 68: 4431-4440.

Hentschel U, Piel J, Degnan SM, Taylor MW (2012) Genomic insights into marine sponge microbiome. *Nat Rev Microbiol* 10: 641–654.

Herr RR, Jahnke HK, Argoudelis AD (1967) Structure of streptozotocin. *J Am Chem Soc* 89: 4808–4809.

Hill RT (2004) Microbes from marine sponges: a treasure trove of biodiversity for natural products discovery. In: *Microbial diversity and bioprospecting* (pp. 225-231). Eds Bull AT. ASM Press

Hohmann C, Schneider K, Bruntner C, Brown R, Jones AL, Goodfellow M, Krämer M, Imhoff JF, Nicholson G, Fiedler HP, Süßmuth RD, (2009a) Albidopyrone, a new alpha-pyrone-containing metabolite from marine-derived *Streptomyces* sp. NTK 227. *J Antibiot* 62: 75–79.

Hohmann C, Schneider K, Bruntner C, Irran E, Nicholson G, Bull AT, et al. (2009b) Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain *Streptomyces* sp. NTK 937 J Antibiot 62: 99–104.

Hook LA (1977) Distribution of myxobacters in aquatic habitats of an alkaline bog. [Appl Environ Microbiol](#) 34: 333-5.

Huang YF, Tian L, Fu HW, Hua HM, Pei YH (2006) One new anthraquinone from marine *Streptomyces* sp. FX-58. *Nat Prod Res* 20: 1207–1210.

Iizuka T., Jojima, Y., Fudou, R., and Yamanaka, S. (1998) Isolation of myxobacteria from the marine environment. *FEMS Microbiol Lett* 169: 317–322.

Inagaki F, Suzuki M, Takai K, Oida H, Sakamoto T, Aoki K, Nealson KH, Horikoshi K (2003) Microbial communities associated with geological horizons in coastal subseafloor sediments from the Sea of Okhotsk. *Appl Environ Microbiol* 69: 7224-7235.

[Irschik H](#), [Gerth K](#), [Kemmer T](#), [Steinmetz H](#), [Reichenbach H](#). (1983) The myxovalgins, new peptide antibiotics from *Myxococcus fulvus* (Myxobacterales). I. Cultivation, isolation, and some chemical and biological properties. *J Antibiot (Tokyo)* 36: 6-12.

[Irschik H](#), [Reichenbach H](#). (1983) The mechanism of action of myxovalargin A, a peptide antibiotic from *Myxococcus fulvus*. *J Antibiot (Tokyo)* 38: 1237-1245.

[Irschik H](#), [Jansen R](#), [Gerth K](#), [Höfle G](#), [Reichenbach H](#) (1987) The sorangicins, novel and powerful inhibitors of eubacterial RNA polymerase isolated from myxobacteria. *J Antibiot (Tokyo)* 0: 7-13.

[Irschik H](#), [Augustiniak H](#), [Gerth K](#), [Höfle G](#), [Reichenbach H](#). (1995) The ripostatins, novel inhibitors of eubacterial RNA polymerase isolated from myxobacteria. *J Antibiot Tokyo* 48: 787-792.

[Irschik H](#), [Schummer D](#), [Höfle G](#), [Reichenbach H](#), [Steinmetz H](#), [Jansen R](#) (2007) Etnangien, a macrolide-polyene antibiotic from *Sorangium cellulosum* that inhibits nucleic acid polymerases *J Nat Prod* 70: 1060-1063.

Jensen, PR, Dwight R, Fenical W (1991) Distribution of actinomycetes in near-shore tropical marine sediments. *Appl Environ Microbiol* 57: 1102–1108.

Jensen PR, Williams PG, Oh DC, Zeigler L, Fenical W (2007) Species-specific secondary metabolite production in marine actinomycetes of the genus *Salinispora*. *Appl Environ Microbiol* 73: 1146–1152.

Jeong SY, Shin HJ, Kim TS, Lee HS, Park S, Kim HM (2006) Streptokordin, a new cytotoxic compound of the methylpyridine class from a marine-derived *Streptomyces* sp. KORDI-3238. *J Antibiot* 59: 234–240.

Jiang S, Sun W, Chen M, Dai S, Zhang L, Liu Y, Lee KJ, Li X (2007) Diversity of culturable actinobacteria isolated from marine sponge *Haliclona* sp. *Antonie van Leeuwenhoek* 92: 405-416.

Jørgensen H, Degnes KF, Dikij A, Fjaervik E, Klinkenberg G, Zotchev SB (2010) Insights into the evolution of macrolactam biosynthesis through cloning and comparative analysis of the biosynthetic gene cluster for a novel macrocyclic lactam, ML-449. *Appl Environ Microbiol* 76: 283–293.

Kanoh K, Matsuo Y, Adachi K, Imagawa H, Nishizawa M, Shizuri Y (2005) Mechercharmycins A and B, cytotoxic substances from marine-derived *Thermoactinomyces* sp. YM3-251. *J Antibiot* 58: 289–92.

Karwehl S, Stadler M (2016): Exploitation of fungal biodiversity for discovery of novel antibiotics. *Curr Top Microbiol Immunol*, in press (doi: 10.1007/82_2016_496)

Kim SB, Oh HM, Kang H, Park SS, Chun J (2004) Remarkable bacterial diversity in the tidal flat sediment as revealed by 16S rDNA analysis. *J Microbiol Biotechnol* 14: 205-211.

Kock I, Maskey RP, Biabani MAF, Helmke E, Laatsch H (2005) 1-Hydroxy-1-norresistomycin and resistoflavin methyl ether: new antibiotics from marine-derived streptomycetes. *J Antibiot* 58: 530–535

[Koutsoudakis G](#), [Romero-Brey I](#), [Berger C](#), [Pérez-Vilaró G](#), [Monteiro Perin P](#), [Vondran FW](#), [Kalesse M](#), [Harmrolfs K](#), [Müller R](#), [Martinez JP](#), [Pietschmann T](#), [Bartenschlager R](#), [Brönstrup M](#), [Meyerhans A](#), [Díez J](#) (2015) Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity. *J Hepatol* 63: 813-821.

[Kunze B](#), [Kemmer T](#), [Höfle G](#), [Reichenbach H](#) (1984) Stigmatellin, a new antibiotic from *Stigmatella aurantiaca* (Myxobacteriales). I. Production, physico-chemical and biological properties. *J Antibiot* (Tokyo) 37: 454-461.

[Kunze B](#), [Höfle G](#), [Reichenbach H](#) (1987) The aurachins, new quinoline antibiotics from myxobacteria: production, physico-chemical and biological properties.

1

J Antibiot (Tokyo) 40: 258-265.

[Kunze B](#), [Jansen R](#), [Höfle G](#), [Reichenbach H](#) (1994) Crocacin, a new electron transport inhibitor from *Chondromyces crocatus* (myxobacteria). Production, isolation, physico-chemical and biological properties. *J Antibiot* (Tokyo) 47: 881-886.

[Kunze B](#), [Jansen R](#), [Sasse F](#), [Höfle G](#), [Reichenbach H](#). (1995) Chondramides A approximately D, new antifungal and cytostatic depsipeptides from *Chondromyces crocatus* (myxobacteria). Production, physico-chemical and biological properties. *J Antibiot* (Tokyo) 48: 1262-1266.

[Kunze B](#), [Reichenbach H](#), [Müller R](#), [Höfle G](#). (2005) Aurafuron A and B, new bioactive polyketides from *Stigmatella aurantiaca* and *Archangium gephyra* (myxobacteria). Fermentation, isolation, physico-chemical properties, structure and biological activity. *J Antibiot* (Tokyo) 58: 244-251.

Kwon, H.C. et al. (2006) Marinomycins A-D, antitumor-antibiotics of a new structure class from a marine actinomycete of the recently discovered genus “*Marinospora*”. *J Am Chem Soc* 128: 1622–1632.

Lam KS (2006) Discovery of novel metabolites from marine actinomycetes. *Curr Opin Microbiol* 9: 245–251.

Li DH, Zhu TJ, Liu HB, Fang YC, Gu QQ, Zhu WM. Four butenolides are novel cytotoxic compounds isolated from the marine-derived bacterium, *Streptoverticillium luteovorticillatum* 11014. *Arch Pharmacol Res* 29: 624–626.

Li F, Maskey RP, Qin S, Sattler I, Fiebig HH, Maier A, et al. (2005) Chinikomycins A and B: isolation structure elucidation, and biological activity of novel antibiotics from a marine *Streptomyces* sp. isolate M045. *J Nat Prod* 68: 349–53.

Link HF (1809) Observations in Ordines plantarum naturales. Dissertatio prima, complectens Anandrarum ordines Epiphytas, Mucedines Gastomycos et Fungos. Der Gesellschaft Naturforschender Freunde zu Berlin Magazin für die neuesten Entdeckungen in der gesamten Naturkunde 3,3-42+2.

Lu J, Ma Y, Liang J, Xing Y, Xi T, Lu Y (2012) Aureolic acids from a marine-derived *Streptomyces* sp. WBF16. *Microbiol Res* 167: 590–595.

Lubsanova D, et al. (2014). Filamentous actinobacteria of the saline soils of arid territories. *Moscow University soil science bulletin* 69: 88-92.

Maldonado LA, Fenical W, Jensen PR, Kauffman CA, Mincer TJ, Bull AT, Ward AC, Goodfellow M (2005a) *Salinispora arenicola* gen. nov., sp nov and *Salinispora tropica* sp nov., obligate marine actinomycetes belonging to the family Micromonosporaceae. *Int J Syst Evol Microbiol* 55: 1759-1766.

Maldonado, LA, Starch JEM, Pathom-aree W, Ward AC, Bill AT, Goodfellow M (2005b) The diversity of cultivable actinobacteria in geographically widespread marine sediments. *Antonie Van Leeuwenhoek* 87: 11–18.

Mantalvo NF, Mohamed NM, Enticknap JJ, Hill RT (2005) Novel actinobacteria from marine sponges. *Antonie van Leeuwenhoek* 87: 29-36.

Manivasagan P, Venkatesan J, Sivakumar K, Kim S-K (2013) Marine actinobacterial metabolites: Current status and future perspectives. *Microbiol Res* 168: 311-332.

Macherla VR, Liu J, Bellows C, Teisan S, Nicholson B, Lam KS, et al. (2005) Glaciapyrroles A, B and C, pyrrololosquiterpenes from a *Streptomyces* sp. isolated from an Alaskan marine sediment. *J Nat Prod* 68: 780–783.

Magarvey NA, Keller JM, Bernan V, Dworkin M, Sherman DH (2004) Isolation and characterization of novel marine-derived actinomycete taxa rich in bioactive metabolites. *Appl Environ Microbiol* 70: 7520-7529.

Manam RR, Teisan S, White DJ, Nishino T, Grodberg J, Neuteboom STC et al. (2005) Lajollamycin, a nitro-tetraene spiro-b-lactone-g-lactam antibiotic from the marine actinomycete *Streptomyces nodosus*. *J Nat Prod* 68: 240–243.

Mao Y, Varoglu M, Sherman DH (1999) Molecular characterization and analysis of the biosynthetic gene cluster for the antitumor antibiotic mitomycin C from *Streptomyces lavendulae* NRRL 2564. *Chem Biol* 6: 251–263.

[Martinez JP](#), [Hinkelmann B](#), [Fleta-Soriano E](#), [Steinmetz H](#), [Jansen R](#), [Diez J](#), [Frank R](#), [Sasse F](#), [Meyerhans A](#) (2013) Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay. [Microb Cell Fact](#) 12: 85.

McArthur KA, Mitchell SS, Tsueng G, Rheingold A, White DJ, Grodberg J, Lam KS, Potts BC (2008) Lynamycins A–E, chlorinated bisindole pyrrole antibiotics from a novel marine actinomycete. *J Nat Prod* 71: 1732–1737.

Mincer TJ, Jensen PR, Kauffman CA, Fenical W (2002) Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments. *Appl Environ Microbiol* 68: 5005–5011.

Mincer TJ, Fenical W, Jensen PR (2005) Culture-dependent and culture-independent diversity within the obligate marine actinomycete genus *Salinispora*. *Appl Environ Microbiol* 71: 7019-7028.

Mitchell SS, Nicholson B, Teisan S, Lam KS, Potts BC (2004) Aureovorticillactam, a novel 22-atom macrocyclic lactam from the marine actinomycete *Streptomyces aureovorticillatus*. *J Nat Prod* 67: 1400–1402.

Mohammadipanah F, Wink J (2016) Actinobacteria from arid and desert habitats: diversity and biological activity. *Frontiers in Microbiology* 6:1541.

Moore BS, Trischman JA, Seng D, Kho D, Jensen PR, Fenical W (1999) Salinamides, antiinflammatory depsipeptides from a marine *Streptomyces*. *J Org Chem* 64: 1145–1150.

Moore BS, Kalaitzis JA, Xiang L (2005) Exploiting marine actinomycete biosynthetic pathways for drug discovery. *Antonie van Leeuwenhoek* 87: 49-57.

[Müller R](#), [Wink J](#) (2014) Future potential for anti-infectives from bacteria - how to exploit biodiversity and genomic potential, *Int J Med Microbiol* 304: 3-13.

Neilson, J.W., et al., (2012) Life at the hyperarid margin: novel bacterial diversity in arid soils of the Atacama Desert, Chile. *Extremophiles* 16: 553-566.

Oh DC, Gontang EA, Kauffman CA, Jensen PR, Fenical W (2008) Salinipyrone and pacificanone, mixed-precursor polyketides from the marine actinomycete *Salinispora pacifica*. *J Nat Prod* 71: 570–575.

[Ojika M](#), [Suzuki Y](#), [Tsukamoto A](#), [Sakagami Y](#), [Fudou R](#), [Yoshimura T](#), [Yamanaka S](#). (1998) Cystothiazoles A and B, new bithiazole-type antibiotics from the myxobacterium *Cystobacter fuscus*, *J Antibiot* (Tokyo) 51: 275-281.

Okami Y, Okazaki T (1972) Studies on marine microorganisms. *J Antibiot* 25: 456-460.

Okoror CK, Brown R, Jones AL, Andrews BA, Asenjo JA, Goodfellow M, Bull AT (2009) Diversity of culturable actinomycetes in hyper arid soils of the Atacama Desert, Chile. *Antonie van Leeuwenhoek* 95: 121-133.

Omura S, Nakagawa A, Fujimoto T, Saito K, Otaguro K, Walsh JC, et al. (1987) Hygromycin A, an antitreponemal substance. I. Screening method and therapeutic effect for *Treponema hyodysenteriae*-caused infection in CF-1 mice. *J Antibiot* 40: 1619.

Oxford AE (1947) [Observations concerning the growth and metabolic activities of myxococci in a simple protein-free liquid medium](#). *J Bacteriol* 53: 129-138.

Pathom-aree W, Stach JEM, Ward AC, Horikoshi K, Bull AT, Goodfellow, M (2006) Diversity of actinomycetes isolated from Challenger Deep sediment (10,898 m) from the Mariana Trench. *Extremophiles* 10: 181-189.

Papineau D, Walker JJ, Mojzsis SJ, Pace NR (2005) Composition and structure of microbial communities from stromatolites of Hamelin Pool in Shark Bay, Western Australia. *Appl Environ Microbiol* 71: 4822-4832.

Perez Baz J, Cañedo LM, Fernández Puentes JL, Silva Elipse MV (1997) Thiocoraline, a novel depsipeptide with antitumor activity produced by a marine *Micromonospora*. II. Physico-chemical properties and structure determination. *J Antibiot* 50: 738–741.

Peschke U, Schmidt H, Zhang HZ, Piepersberg W (2006) Molecular characterization of the lincomycin-production gene cluster of *Streptomyces lincolnensis* 78-11. *Mol Microbiol* 16:1137–1156.

Piel J, Hertweck C, Shipley PR, Hunt DM, Newman MS, Moore BS (2000) Cloning, sequencing and analysis of the enterocin biosynthesis gene cluster from the marine isolate '*Streptomyces maritimus*': evidence for the derailment of an aromatic polyketide synthase. *Chem Biol* 7: 943–955.

[Pivot X](#), [Dufresne A](#), [Villanueva C](#). (2007) Efficacy and safety of ixabepilone, a novel epothilone analogue. [Clin](#) Breast Canc 7: 543-549.

Prudhomme J, McDaniel E, Ponts N, Bertani S, Fenical W, Jensen P, et al. (2008) Marine actinomycetes: a new source of compounds against the human malaria parasite. *PLoS One* 3: 2335.

Rachid S, Huo L, Herrmann J, Stadler M, Köpcke B, Bitzer J, Müller R (2011) Mining the cinnabaramide biosynthetic pathway to generate novel proteasome inhibitors. *ChemBioChem* 12: 922-931.

Reichenbach H, Gerth K, Irschik H, Kunze B, Höfle G (1988) Myxobacteria: a source of new antibiotics. *Trends Biotechnol* 6:115-121.

Reichenbach H, Dworkin M (1981) The order Myxobacteriales In: *The Prokaryotes* (Vol.I) (pp. 328-355). Eds Starr, MP Stolp H, Trüper HG, Balows A Schlegel HG. Springer, Berlin

Reichenbach H (1983) A simple method for the purification of myxobacteria. *J Microbiol Methods* 1: 77-79.

Reichenbach H and Dworkin M (1991) The Myxobacteria In: *The Prokaryotes* (Vol.4) (pp.3415-3487). Eds Barlows A, Trüper HG, Dworkin M, Harder W, Schleifer K-H. Springer, New York

Reichenbach H, Höfle G (1993) Biologically Active Secondary Metabolites from Myxobacteria, *Biotech Adv* 11: 219-277.

Reichenbach H, Lang E, Schumann P, Spröer C (2006) *Byssovorax cruenta* gen. nov., sp. nov., nom. rev., an cellulose-degrading myxobacterium: rediscovery of '*Myxococcus cruentus*' Thaxter 1897. *Int J Syst and Evol Microbio* 56: 2357–2363.

Reichenbach H, Dworkin M, Shimkets LJ (2006) The Myxobacteria In: *The Prokaryotes* (Vol.7) (pp. 31-115). Eds Dworkin M, Falkow S, Rosenberg E, Schleifer K.-H. Stackebrandt E. Springer, Berlin

Reichenbach H and Höfle G (2008) Discovery and development of the epothilones : a novel class of antineoplastic drugs. *Drugs R D*. 9: 1-10.

Ringel SM, Greenough RC, Roemer S (1977) Ambruticin (W7783), a new antifungal antibiotic. *J Antibiot* 30: 371-375.

Saleh EA, Mahmoud SAZ, el-Haddad ME, Abdel-Fatah MK (1985) Purification and identification of *Streptomyces aureofaciens* ID13 antibiotic. *Zentralblatt für Mikrobiologie* 140: 325–332.

[Sanford RA](#), [Cole JR](#), [Tiedje JM](#) (2002) Characterization and description of *Anaeromyxobacter dehalogenans* gen. nov., sp. nov., an aryl-halo-respiring facultative anaerobic myxobacterium, *Appl Environ Microbiol* 68: 893-900.

[Sasse F](#), [Steinmetz H](#), [Höfle G](#), [Reichenbach H](#) (1993) Rhizopodin, a new compound from *Myxococcus stipitatus* (myxobacteria) causes formation of rhizopodia-like structures in animal cell cultures. Production, isolation, physico-chemical and biological properties, *J Antibiot* 46: 741-748.

[Sasse F](#), [Böhlendorf B](#), [Herrmann M](#), [Kunze B](#), [Forche E](#), [Steinmetz H](#), [Höfle G](#), [Reichenbach H](#). (1999) Melithiazols, new beta-methoxyacrylate inhibitors of the respiratory chain isolated from myxobacteria. Production, isolation, physico-chemical and biological properties *J Antibiot* 52: 721-729.

Schreurs M, Van Dijk TH, Gerding A, Havinga R, Reijngoud DJ, Kuipers F (2009) Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high-fat diet. *Diabetes Obes Metab* 11: 987–991.

Selvin J, Joseph S, Asha KRT, Manjusha WA, Sangeetha VS, Jayaseema DM, Antony MC, Denslin Vinitha AJ (2004) Antibacterial potential of antagonistic *Streptomyces* sp. isolated from marine sponge *Dendrilla nigra*. *FEMS Microbiol Ecol* 50: 117-122.

[Schneiker S](#), [Perlova O](#), [Kaiser O](#), [Gerth K](#), [Alici A](#), [Altmeyer MO](#), [Bartels D](#), [Bekel T](#), [Beyer S](#), [Bode E](#), [Bode HB](#), [Bolten CJ](#), [Choudhuri JV](#), [Doss S](#), [Elnakady YA](#), [Frank B](#), [Gaigalat L](#), [Goesmann A](#), [Groeger C](#), [Gross F](#), [Jelsbak L](#), [Jelsbak L](#), [Kalinowski J](#), [Kegler C](#), [Knauber T](#), [Konietzny S](#), [Kopp M](#), [Krause L](#), [Krug D](#), [Linke B](#), [Mahmud T](#), [Martinez-Arias R](#), [McHardy AC](#), [Merai M](#), [Meyer F](#), [Mormann S](#), [Muñoz-Dorado J](#), [Perez J](#), [Pradella S](#), [Rachid S](#), [Raddatz G](#), [Rosenau F](#), [Rückert C](#), [Sasse F](#), [Scharfe M](#), [Schuster SC](#), [Suen G](#), [Treuner-Lange A](#), [Velicer GJ](#), [Vorhölter FJ](#), [Weissman KJ](#), [Welch RD](#), [Wenzel](#)

[SC](#), [Whitworth DE](#), [Wilhelm S](#), [Wittmann C](#), [Blöcker H](#), [Pühler A](#), [Müller R](#) (2007) Complete genome sequence of the myxobacterium *Sorangium cellulosum*. *Nat Biotechnol* 25: 1281-1289.

Schultz AW, Oh DC, Carney JR, Williamson, RT, Udvary DW, Jensen PR, Gould SJ, Fenical W, Moore BS (2008) Biosynthesis and structures of cyclomarins and cyclomarazines, prenylated cyclic peptides of marine actinobacterial origin. *J Am Chem Soc* 130: 4507–4516.

Shimkets L J, Dworkin M, Reichbach H (2004) *The myxobacteria*, 3rd ed. Springer, New York

Singh BN (1947) Myxobacteria in soils and composts; the distribution, number and lytic action on bacteria. *J Gen Microbiol* 1: 1-10.

Sivakumar K, Sahu MK, Thangaradjou T, Kannan L (2007) Research on marine actinobacteria in India. *Ind J Microbiol* 47: 186–196.

Socha AM, LaPlante KL, Rowley DC (2006) New bisanthraquinone antibiotics and semisynthetic derivatives with potent activity against clinical *Staphylococcus aureus* and *Enterococcus faecium* isolates. *Bioorganic Med Chem* 14: 8446–54.

Soria-Mercado IE, Prieto-Davo A, Jensen PR, Fenical W (2005) Antibiotic terpenoid chlorodihydroquinones from a new marine actinomycete. *J Nat Prod* 68: 904–910.

Stach JEM, Maldonado LA, Masson DG, Ward AC, Goodfellow M, Bull AT (2003) Statistical approaches to estimating bacterial diversity in marine sediments. *Appl Environ Microbiol* 69: 6189-6200.

Stach JEM and Bull AT (2005) Estimating and comparing the diversity of marine actinobacteria. *Antonie van Leeuwenhoek* 87, 3–9.

Stadler M, Bitzer J, Mayer-Bartschmid A, Müller H, Benet-Buchholz J, Gantner F, Tichy HV, Reinemer P, Bacon KB (2007) Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomyces. *J Nat Prod* 70: 246-252.

Steinert G, Whitfield S, Taylor MW, Thoms C, Schupp PJ (2014) Application of diffusion growth chambers for the cultivation of marine sponge-associated bacteria. *Mar Biotechnol*. Springer, 16: 594-603.

[Surup F](#), [Viehrig K](#), [Mohr KI](#), [Herrmann J](#), [Jansen R](#), [Müller R](#) (2014) Disciformycins A and B: 12-membered macrolide glycoside antibiotics from the myxobacterium *Pyxidicoccus fallax* active against multiresistant staphylococci. *Angew Chem Int Ed* 53: 13588-13591.

Takami H, Inoue A, Fuji F, Horikoshi K (1997) Microbial flora in the deepest sea mud of the Mariana Trench. *FEMS Microbiol Lett* 152: 279-285.

Takizawa M, Colwell RR, Hill RT (1993) Isolation and Diversity of Actinomycetes in the Chesapeake Bay. *Appl. Environm Micobiol* 59: 997-1002.

Thaxter R (1892) On the Myxobacteriaceae, a new order of Schizomycetes. *Bot Gaz* 17: 389-406.

Uyeda M, Mizukami M, Yokomizo K, Suzuki K, Pentalenolactone I (2001) Hygromycin A. immunosuppressants produced by *Streptomyces filipinensis* and *Streptomyces hygroscopicus*. *Biosci Biotechnol Biochem* 65:1252–1254.

[Vetcher L](#), [Hugo G. Menzella](#), [Toshiaki Kudo](#), [Takayuki Motoyama](#), and [Leonard Katz](#) (2013) The antifungal polyketide ambruticin targets the HOG pathway, *Antimicrob Agents Chemother* 51: 3734–3736.

- Vezina C, Kudelski A, Sehgal S (1975) Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. *J Antibiot* 28: 721–726.
- Ward AC and Bora N (2006) Diversity and biogeography of marine actinobacteria. *Curr Opin Microbiol* 9: 279-286.
- Webster NS, Hill RT (2001) The culturable microbial community of the great barrier reef sponge *Rhopaloeides odorabile*. *Appl Environ Microbiol* 138: 843-851.
- Webster NS, Taylor MW (2012) Marine sponges and their microbial symbionts: love and other relationships *Environ Microbiol* 14: 335–46.
- Weissmann KJ, Müller R (2009) A brief tour of myxobacterial secondary metabolism. *Bioorg Med Chem* 17: 2121-2136.
- [Wenzel SC](#), [Müller R](#) (2009) The impact of genomics on the exploitation of the myxobacterial secondary metabolome. [Nat](#) Prod Rep 26: 1385-1407.
- Werner G, Hagenmaier H, Drautz H, Baumgartner A, Zähler H (1984) Metabolic products of microorganisms. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity. *J Antibiot* 37: 110-117.
- Wu SJ, Fotso S, Li F, Qin S, Kelter T, Fiebig HH, et al. (2006) 39-N-carboxamidostaurosporine and selina-4(14),7(11)-diene-8,9-diol, new metabolites from a marine *Streptomyces* sp. *J Antibiot* 59: 331–337.
- Wu Z, Xie L, Xia G, Zhang J, Nie Y, Hu J, Wang S, Zhang R (2005) A new tetrodotoxin-producing actinomycete, *Nocardiopsis dassonvillei*, isolated from the ovaries of pufferfish *Fugu rubripes*. *Taxoicon* 45: 851-859.